Curium Pharma announces acquisition of Monrol
Ella Day | April 3, 2025 | News story | Manufacturing and Production, Research and Development | Curium Pharma, Monrol, Oncology, acquisition, nuclear medicine, radiopharmaceutical products
Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine player.
With facilities across Europe and the US, Curium develops, manufactures and distributes radiopharmaceutical products to help patients with life-threatening diseases. It is a contract development and manufacturing organisation (CDMO) and offers single photon emission computed tomography (SPECT), positron emission tomography (PET) and therapeutic radiopharma solutions.
Based in Istanbul, Turkey, Monrol provides radioisotopes and radiopharmaceutical products. It is both a contract manufacturing organisation (CMO) and CDMO.
The acquisition will enrich Curium’s research and development of theranostic products, specifically the manufacturing of Lutetium-177 (Lu-177), and security of the future launch of the company’s Lu-177 drug candidates. The candidate for prostate cancer is currently under development and the one for neuroendocrine tumours is awaiting approval.
Moreover, Curium intends to utilise Monrol’s manufacturing and logistics infrastructure for its production and distribution capabilities. It plans to deploy Monrol’s Ga-68 generation, which is pending regulatory approvals.
Chaitanya Tatineni, Curium’s chief executive officer of international markets, commented: “The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu-177, and create multiple new opportunities to enhance our offering of life-changing diagnostic and therapeutic solutions to patients around the world.”
Aydin Kucuk, general manager at Monrol, added: “We are excited to be joining Curium and have long admired the company’s capabilities, leadership and commitment to developing and supplying world-class nuclear diagnostics solutions and therapies.”
Ella Day
3/4/25
Related Content
Alan Perkins awarded MBE for services to patient care and clinical science
Serac Life Sciences has announced that Alan Perkins, scientific advisor to its subsidiaries Serac Healthcare …
Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …
Enosium Life Science acquires RWEality
Enosium Life Science, which specialises in life sciences, has acquired RWEality, a consultancy focused on …
